Sep 10 2019
Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and striatum of brains. α-synuclein is the causative protein of Parkinson's disease. Ubiquitinated α-synuclein aggregates in nerve cells play a central role in the development of disease. A research team at Niigata University has discovered that G3BP1 protein inhibits ubiquitination and aggregation of α-synuclein. This study suggested that the G3BP1 plays a protective role in the development of Parkinson's disease by reducing α-synuclein ubiquitination and aggregation. Therefore, G3BP1 is a promising drug target for the treatment of Parkinson's disease.
Title:?G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10
Journal:?Scientific Reports
Authors:?Sergei Anisimov, Masahiko Takahashi, Taichi Kakihana,Yoshinori Katsuragi, Hiroki Kitaura, Lu Zhang, Akiyoshi Kakita, Masahiro Fujii
Temozolomide and radiation treatment lead to dramatic tumor shrinkage and improvement of hearing in an adult brainstem glioma patient with a rare IDH2 mutation
Fertilizable rat sperm produced in a mouse body by blastocyst complementation
Estimating Microbial Biomass from Air-Dried Soils: A Safer, Scalable Approach ーRevolutionary Technique Estimates Soil Microbial Biomass Using Water-Extractable Organic Matterー